

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

Ultra-LEAF(TM) Purified anti-mouse CD28

RRID:AB_11147170

Type: Antibody

Proper Citation

(BioLegend Cat# 102116, RRID:AB_11147170)

Antibody Information

URL: http://antibodyregistry.org/AB_11147170

Proper Citation: (BioLegend Cat# 102116, RRID:AB_11147170)

Target Antigen: CD28

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC, IP, IHC-F, Costim, Block

Antibody Name: Ultra-LEAF(TM) Purified anti-mouse CD28

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: Clone 37.51

Antibody ID: AB_11147170

Vendor: BioLegend

Catalog Number: 102116

Alternative Catalog Numbers: 102121, 102132, 102131, 102122, 102115

Record Creation Time: 20260526T044338+0000

Record Last Update: 20260526T044338+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-mouse CD28.

No alerts have been found for Ultra-LEAF(TM) Purified anti-mouse CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 81 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chemla Y, et al. (2026) HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion. *Cell*, 189(1), 233.

Li X, et al. (2026) The TCR-SUB1-DOCK2 axis promotes autoimmunity by driving pathogenic CD4+ T cell tissue infiltration. *Immunity*, 59(1), 98.

Rainwater RR, et al. (2026) DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. *Cell reports*, 45(1), 116796.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.

Brown ME, et al. (2025) Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function. *Diabetologia*, 68(2), 397.

Kim DH, et al. (2025) Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis. *Cell reports. Medicine*, 6(4), 102047.

Kandasamy M, et al. (2025) Glycogen synthase kinase-3 is essential for Treg development and function. *Cell reports*, 44(9), 116256.

Hesterberg RS, et al. (2025) Lymphoma accelerates T cell and tissue aging. *Cancer cell*.

Li H, et al. (2025) T cell-intrinsic cGAS-CTCF regulation maintains regulatory T cell development and function. *Cell reports*, 44(10), 116302.

Qiu Y, et al. (2025) Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. *Cancer cell*, 43(1), 103.

Tripathi A, et al. (2025) Nrf2 drives activation-driven expansion of CD4+T cells by modulating glucose and glutamine metabolism. *Cell reports*, 44(9), 116177.

Bündgen G, et al. (2025) Polyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells. *Immunity*, 58(8), 2019.

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8⁺T cell dysfunction via FGF21-driven lipolysis. *Cell reports*, 44(11), 116526.

Cohen JA, et al. (2025) KMT2D coordinates antiviral CD4⁺ T cell responses through opposing effects on T follicular helper and cytotoxic gene expression. *Cell reports*, 44(6), 115775.

Cole AC, et al. (2025) Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity. *Cancer cell*, 43(9), 1697.

Ma K, et al. (2025) Succinate preserves CD8⁺ T cell fitness to augment antitumor immunity. *Immunity*.

Leng F, et al. (2025) Ultrastable and versatile multimeric ensembles of FoxP3 on microsatellites. *Molecular cell*, 85(8), 1509.

Sheban F, et al. (2025) ZEB2 is a master switch controlling the tumor-associated macrophage program. *Cancer cell*, 43(7), 1227.

Yu S, et al. (2025) Caveolin-1/PPAR γ axis suppresses T follicular helper cell response in primary Sjögren disease. *Cell reports*, 44(8), 116156.

Wang M, et al. (2025) Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors. *Cancer discovery*, 15(9), 1883.